Clinical Trial Update: Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr [Phase 2]

View source ↗

Summary

A Phase 2 double-blind, placebo-controlled dose-ranging trial evaluated SSR149744c at 300 mg or 600 mg for converting atrial fibrillation or atrial flutter to s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter

Drugs mentioned

• SSR149744c (SSR149744c)

Snippet

Sponsor: Sanofi | Conditions: Atrial Fibrillation, Atrial Flutter | Phase 2 | Status: COMPLETED